Michael Makris/LinkedIn
Feb 28, 2026, 16:16
Michael Makris: Lower Doses of Hemlibra May Still Be Effective
Michael Makris, Emeritus Professor of Haemostasis and Thrombosis at the University of Sheffield, shared on LinkedIn about his recent commentary, adding:
”The approved dose of Hemlibra (emicizumab) is generous, and smaller doses are likely to be effective.
You can read the arguments in my commentary published in the current issue of the Journal of Thrombosis and Haemostasis.”
Title: Is all the approved emicizumab dose essential?
Authors: Michael Makris
Read the Full Article on JTH
Stay updated on all scientific advances with Hemostasis Today.
-
May 31, 2026, 07:02Raising Awareness of Cerebral Venous Sinus Thrombosis in Women – NBCA
-
May 31, 2026, 07:00Ceri Roberts: How to Reduce Your Risk of a Blood Clot
-
May 31, 2026, 05:28Nikolaos Androulakis: Inflammatory Burden and Antiphospholipid Antibodies in Lupus Anticoagulant Testing
-
May 31, 2026, 05:28Alysha Arif: Understanding a Complex Case of Postpartum Seizures
-
May 31, 2026, 05:27Chiara Novelli: Are We Validating Laboratory Algorithms as Rigorously as We Validate Laboratory Tests?
-
May 31, 2026, 02:42Katja van den Hurk: Optimizing Iron Management in Blood Donors
-
May 31, 2026, 02:36The New JPAC Website Has Been Live for Nearly a Week – SHOT
-
May 31, 2026, 02:33Jecko Thachil: Is It Possible to Use Machine Learning for Differentiating Inherited Thrombocytopenia from Other Causes?
-
May 30, 2026, 18:12Khokon Miah Akanda: FDA Approves a First-in-Class Hypertension Drug